ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
ENANTA PHARMACEUTICALS INC
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.41+0.31 (+2.79%)
Close on Oct 19, 2026
- Market cap
- $331.92M
- P/E (TTM)
- –
- Dividend yield
- –
ENANTA PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty [Member] | $14.36M | $17.16M | $18.62M | $15.13M | $18.31M | $16.96M | $14.61M | $17.97M | $17.05M | $18.00M | $18.93M | $18.89M | 100.0% | -21.6% |
| License [Member] | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Enanta Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.